Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia.
J Diabetes Sci Technol
; 15(5): 1181-1187, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1280566
ABSTRACT
Complications of Coronavirus Disease 2019 (COVID-19) occur with increased frequency in people admitted to the hospital with diabetes or hyperglycemia. The increased risk for COVID-19 infections in the presence of these metabolic conditions is in part due to overlapping pathophysiologic features of COVID-19, diabetes, and glucose control. Various antiviral treatments are being tested in COVID-19 patients. We believe that in these trials, it will be useful to evaluate treatment effect differences in patients stratified according to whether they have diabetes or hyperglycemia. In this way, it will be possible to better facilitate development of antiviral treatments that are most specifically beneficial for the large subset of COVID-19 patients who have diabetes or hyperglycemia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Clinical Trials as Topic
/
Diabetes Mellitus
/
COVID-19
/
Hyperglycemia
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Diabetes Sci Technol
Journal subject:
Endocrinology
Year:
2021
Document Type:
Article
Affiliation country:
19322968211013369
Similar
MEDLINE
...
LILACS
LIS